AGNOS: An 18-month, Open-label, Multi-Center Study to Assess the Effect of Ofatumumab 20mg SC Monthly in Treatment Naïve, Very Early Relapsing Remitting Multiple Sclerosis Patients Benchmarked Against Healthy Controls on Select Outcomes
Latest Information Update: 25 Sep 2024
At a glance
- Drugs Ofatumumab (Primary)
- Indications Multiple sclerosis
- Focus Therapeutic Use
- Acronyms AGNOS
- Sponsors Novartis Pharmaceuticals
- 20 May 2024 Planned primary completion date changed from 21 Feb 2025 to 17 Feb 2025.
- 08 May 2024 Status changed from recruiting to active, no longer recruiting.
- 01 Feb 2024 Planned End Date changed from 22 Jun 2026 to 16 Feb 2026.